Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT00231478
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 896
- Registration Number
- NCT00192647
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00148915
- Locations
- 🇺🇸
GSK Investigational Site, Duncansville, Pennsylvania, United States
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT00129623
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 157
- Registration Number
- NCT00127933
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2011-04-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 109
- Registration Number
- NCT00121836
Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT00121810
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT00121784
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 293
- Registration Number
- NCT00118742
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2011-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 435
- Registration Number
- NCT00118755
© Copyright 2024. All Rights Reserved by MedPath